Paul Tudor Jones Terns Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 15,753 shares of TERN stock, worth $134,688. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,753Holding current value
$134,688% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TERN
# of Institutions
132Shares Held
63.4MCall Options Held
413KPut Options Held
106K-
Orbimed Advisors LLC San Diego, CA7.62MShares$65.1 Million1.25% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.18MShares$52.9 Million6.22% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$52.2 Million1.36% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.95MShares$42.3 Million3.41% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$35.2 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $322M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...